N.y. Chiropractic Care, P.c. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 4828 202nd St, Oakland Gardens, NY 11364 Phone: 718-819-2920 |
Dr. Steven Chen, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 6426 229th St, Oakland Gardens, NY 11364 Phone: 917-751-0841 |
Hillside Family Chiropractic, P.c. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 48 28 202 St., Oakland Gardens, NY 11364 Phone: 718-819-2920 |
Warren Albert, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 4828 202nd St, Oakland Gardens, NY 11364 Phone: 718-819-2920 |
News Archive
In this post on the Center for Global Development's (CGD) "Global Health Policy" blog, Mead Over, economist and senior fellow at CGD, previews his participation in a panel that took place Monday evening at the XIX International AIDS Conference.
Florida Republican leaders made a clear statement during a special legislative session Tuesday: They want to overhaul the Medicaid program and don't want the federal government tying their hands. But that might ignore Washington realities. Congress this year required states to increase the number of people eligible for Medicaid in the future — the opposite of giving Florida more flexibility to run the program.
The Life Sciences Discovery Fund today announced $1.2 million in Proof of Concept grants to Washington-based organizations to foster the advancement of promising health-related technologies to commercial products. Also announced were two commercialization-focused awards, totaling $600,000, through a new funding program requiring external cash matching.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
› Verified 3 days ago